Skip to content
Agree.net – Lifestyle
Author:
ITM Isotope Technologies Munich SE
/C O R R E C T I O N — SAXX/
March 27, 2026
ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference
March 7, 2026
←
Previous Page
1
2